Profile data is unavailable for this security.
About the company
Biocytogen Pharmaceuticals Beijing Co Ltd is a China-based company mainly engaged in drug development business and preclinical research. The Company operates its business through five segments. The Gene-editing Services segment provides the customized gene-editing services based on animals as well as cells. The Pre-clinical Pharmacology and Efficacy Evaluation segment provides preclinical pharmacology services for the evaluation of drug efficacy and toxicity. The Animal Models Selling segment breeds and sells the animal models for the external and internal use. The Antibody Development segment utilises its antibody discovery platforms to identify antibodies which have the potential to become drug candidates. The Innovative Drugs Development segment is engaged in research and development of innovative drugs with a focus on oncology and autoimmune disease therapeutics.
- Revenue in HKD (TTM)859.97m
- Net income in HKD-261.91m
- Incorporated2009
- Employees1.04k
- LocationBiocytogen Pharmaceuticals Beijing Co LtdNo. 12Baocan South Street, Daxing DistrictBeijing 101111ChinaCHN
- Phone+86 1 056967666
- Fax+86 1 056315306
- Websitehttps://www.biocytogen.com.cn/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jacobio Pharmaceuticals Group Co Ltd | 24.91m | -388.74m | 1.29bn | 298.00 | -- | 1.33 | -- | 51.63 | -0.5008 | -0.5008 | 0.0321 | 1.23 | 0.016 | -- | 2.41 | 82,741.46 | -24.89 | -45.76 | -28.66 | -49.30 | 3.45 | -- | -1,560.88 | -372.22 | -- | -- | 0.1794 | -- | -33.66 | -- | 3.43 | -- | 19.18 | -- |
| Mabpharm Ltd | 162.87m | -222.28m | 1.38bn | 297.00 | -- | 11.17 | -- | 8.48 | -0.0539 | -0.0539 | 0.0395 | 0.03 | 0.164 | 0.1937 | 3.26 | 469,376.20 | -22.38 | -21.42 | -31.11 | -27.49 | 86.91 | -- | -136.47 | -486.40 | 0.6836 | -22.44 | 0.679 | -- | 55.87 | -- | 0.694 | -- | -26.85 | -- |
| TOT Biopharm International Co Ltd | 1.05bn | 9.63m | 1.46bn | 572.00 | 142.35 | 1.88 | 21.41 | 1.40 | 0.0133 | 0.0133 | 1.44 | 1.01 | 0.6899 | 2.44 | 6.40 | 1,897,227.00 | 0.6356 | -20.01 | 0.8392 | -25.21 | 72.02 | 74.74 | 0.9212 | -68.53 | 1.63 | 2.98 | 0.3465 | -- | 76.54 | 81.88 | 24.36 | -- | 21.04 | -- |
| Hua Medicine | 117.02m | -282.92m | 1.65bn | 172.00 | -- | -- | -- | 14.07 | -0.2886 | -0.2886 | 0.1194 | -0.0363 | 0.0779 | 1.51 | 3.31 | 661,157.10 | -18.84 | -25.61 | -23.63 | -28.81 | 37.72 | -- | -241.76 | -1,654.70 | 4.64 | -- | 1.14 | -- | 335.31 | -- | -3.80 | -- | 14.07 | -- |
| Qyuns Therapeutics Co Ltd | 48.25m | -453.10m | 1.98bn | 325.00 | -- | 5.02 | -- | 41.10 | -1.93 | -1.93 | 0.219 | 1.78 | -- | -- | -- | 145,775.50 | -- | -- | -- | -- | 84.05 | -- | -976.77 | -- | 1.83 | -29.56 | 0.5795 | -- | -- | -- | -70.28 | -- | -- | -- |
| Frontage Holdings Corp | 2.02bn | 47.47m | 2.18bn | 1.66k | 46.60 | 0.8315 | 6.44 | 1.08 | 0.023 | 0.023 | 0.988 | 1.29 | 0.4701 | 56.23 | 4.58 | 1,150,374.00 | 1.06 | 4.46 | 1.30 | 5.28 | 28.56 | 34.00 | 2.26 | 9.92 | 1.25 | 2.37 | 0.311 | 0.00 | 3.79 | 25.61 | -58.00 | -0.7826 | 40.43 | -- |
| Biocytogen Pharmaceuticals Beijng Co Ltd | 859.97m | -261.91m | 2.40bn | 1.04k | -- | 3.02 | -- | 2.79 | -0.6576 | -0.6576 | 2.16 | 1.99 | 0.3109 | 23.64 | 5.36 | 806,728.50 | -9.47 | -- | -12.44 | -- | 71.97 | -- | -30.46 | -- | 1.33 | -4.18 | 0.436 | -- | 34.28 | -- | 36.38 | -- | -- | -- |
| CStone Pharmaceuticals | 490.40m | -152.87m | 2.56bn | 164.00 | -- | 5.09 | -- | 5.21 | -0.12 | -0.12 | 0.3847 | 0.3912 | 0.2861 | 1.33 | 2.50 | 2,132,195.00 | -8.92 | -54.76 | -16.99 | -81.68 | 70.73 | -- | -31.17 | -301.62 | 1.45 | -- | 0.4171 | -- | -3.64 | -- | 59.32 | -- | 52.42 | -- |
| ImmuneOnco Biopharmaceuticls Shanghi Inc | 404.97k | -402.17m | 2.74bn | 150.00 | -- | 4.25 | -- | 6,772.28 | -1.12 | -1.12 | 0.0011 | 1.72 | -- | -- | -- | 2,792.90 | -- | -- | -- | -- | -- | -- | -99,307.43 | -- | -- | -- | 0.14 | -- | -28.25 | -- | 5.82 | -- | -- | -- |
| Abbisko Cayman Ltd | 534.17m | -17.40m | 3.15bn | 275.00 | -- | 1.41 | 886.04 | 5.89 | -0.0295 | -0.0295 | 0.8225 | 3.27 | 0.2159 | -- | 65.75 | 2,070,417.00 | -0.7034 | -- | -0.733 | -- | 0.00 | -- | -3.26 | -- | -- | -- | 0.0142 | -- | -- | -- | 12.92 | -- | -- | -- |
